{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:50:59Z","timestamp":1789530659333,"version":"build-2803163510"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Lecanemab is a humanized murine IgG1 antibody. Recent Phase 3 clinical trials have demonstrated its ability to reduce brain amyloid-\u03b2 (A\u03b2) load and slow cognitive decline in patients with early Alzheimer\u2019s disease (AD). However, since its approval, reports on adverse effects (AEs) associated with lecanemab have been limited. To better understand the AEs related to lecanemab and provide guidance for future clinical use, we analyzed lecanemab-associated AEs using data from the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We extracted all AEs reports from the FAERS database for the period from the first quarter of 2023 to the third quarter of 2024. Using the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS) algorithms, we conducted a comprehensive analysis of lecanemab-related AEs, restricting the analysis to AEs with the role code of primary suspect (PS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 811 AEs reports related to lecanemab used in AD patients and 506 AEs in Non-AD patients were included. The preferred terms (PTs) identified as positive across all four algorithms included headache, Amyloid Related Imaging Abnormalities-oedema\/effusion (ARIA-E), chills, Amyloid Related Imaging Abnormalities-haemosiderosis\/microhaemorrhage (ARIA-H), fatigue, infusion-related reaction, nausea, pyrexia, pain, influenza like illness, and so on. Among these, ARIA-E, ARIA-H, brain oedema and status epilepticus were associated with Important Medical Events (IMEs) for AD patients, and brain oedema, cerebral haemorrhage, cerebral microhaemorrhage, subdural haematoma, ischaemic stroke, cerebral infarction were associated with IMEs for Non-AD patients. At the system organ class (SOC) level, the highest signal detection for lecanemab was observed in nervous system disorders among AD and Non-AD patients [ROR for AD: 2.42 (2.2\u20132.65); ROR for Non-AD: 6.97 (6.12\u20137.95)]. The median time to the occurrence of these AEs was 44 days after administration in AD patients and 30 days for Non-AD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study utilized the FAERS database to evaluate lecanemab-associated AEs in AD and non-AD patients, along with their temporal patterns post-marketing authorization, thereby establishing a foundation for subsequent clinical pharmacovigilance. A biweekly 10\u00a0mg\/kg was identified as the optimal therapeutic dosage. ARIA emerged as frequent treatment-related AEs, with APOE\u025b4 carriers demonstrating heightened susceptibility. This necessitates serial brain MRI surveillance for all patients during treatment, aimed not only at early ARIA detection but also vigilant monitoring of IMEs including cerebral haemorrhage, cerebral microhaemorrhages, subdural haematoma, cerebral edema, ischaemic stroke, and cerebral infarction. While AD patients predominantly exhibited non-specific clinical manifestations, non-AD cohorts showed elevated risks of stroke-related complications. Consequently, dynamic neurological deficit monitoring is indispensable for non-AD populations receiving lecanemab to mitigate adverse outcomes. Finally, comprehensive reassessment of anticoagulant or antiplatelet therapy indications is warranted in both AD and non-AD patients to reduce hemorrhagic risks.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1559447","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T05:46:45Z","timestamp":1743572805000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab"],"prefix":"10.3389","volume":"16","author":[{"given":"Linlin","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zucai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e061863","DOI":"10.1002\/alz.061863","article-title":"The combined effect of \u03b2 -amyloid and white matter hyperintensities on present and future executive function performance in cognitively normal older adults","volume":"19","author":"Ali","year":"2023","journal-title":"Alzheimer\u2009s Dement"},{"key":"B2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jalz.2016.03.001","article-title":"2016 Alzheimer's disease facts and figures","volume":"12","author":"Alzheimer's","year":"2016","journal-title":"Alzheimers Dement."},{"key":"B3","doi-asserted-by":"publisher","first-page":"102620","DOI":"10.1016\/j.arr.2024.102620","article-title":"Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: a systematic review and meta-analysis","volume":"104","author":"Arroyo-Pacheco","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.14283\/jpad.2022.21","article-title":"Detection and management of amyloid-related imaging abnormalities in P atients with Alzheimer's disease treated with anti-amyloid beta therap y","volume":"9","author":"Barakos","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's dise ase","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.neuroscience.2024.11.029","article-title":"Comparison of the efficacy of updated drugs for the treatment on the i mprovement of cognitive function in patients with Alzheimer 's disease: a systematic review and network meta-analysis","volume":"565","author":"Cao","year":"2025","journal-title":"Neuroscience"},{"key":"B7","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13195-022-01129-x","article-title":"Consistency of efficacy results across various clinical measures and s tatistical methods in the lecanemab phase 2 trial of early Alzheimer's disease","volume":"14","author":"Dhadda","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","article-title":"Amyloid-related imaging abnormalities and \u03b2-amyloid-targeting antibodi es: a systematic review","volume":"79","author":"Filippi","year":"2022","journal-title":"JAMA Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"a024331","DOI":"10.1101\/cshperspect.a024331","article-title":"Antibody therapeutics targeting A\u03b2 and tau","volume":"7","author":"Gallardo","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/archpsyc.63.2.168","article-title":"Role of genes and environments for explaining Alzheimer disease","volume":"63","author":"Gatz","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1002\/alz.13891","article-title":"Decentralized clinical trials for medications to reduce the risk of de mentia: Consensus report and guidance","volume":"20","author":"Howard","year":"2024","journal-title":"Alzheimers Dement."},{"key":"B14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/0018578718795271","article-title":"The newly available FAERS public dashboard: implications for Health Ca re professionals","volume":"54","author":"Kumar","year":"2019","journal-title":"Hosp. Pharm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/amiajnl-2012-001119","article-title":"Comparative analysis of pharmacovigilance methods in the detection of adverse drug reactions using electronic medical records","volume":"20","author":"Liu","year":"2013","journal-title":"J. Am. Med. Inf. Assoc."},{"key":"B16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401--a clinical study in Alzheimer's di sease with a protofibril selective A\u03b2 antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/bmj.p1580","article-title":"Alzheimer's disease: lecanemab gets full FDA approval and black box sa fety warning","volume":"382","author":"Mahase","year":"2023","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/life10080138","article-title":"Comparison of Data Mining Methods for the Signal Detection of Adverse Drug Events with a Hierarchical Structure in Postmarketing Surveillanc e","volume":"10","author":"Park","year":"2020","journal-title":"Life (Basel)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"13954","DOI":"10.3390\/ijms232213954","article-title":"Alzheimer's disease: treatment strategies and their limitations","volume":"23","author":"Passeri","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/alz.069542","article-title":"ALZ-NET: using real world evidence to inform the future of Alzheimer\u2019s treatment and care","volume":"18","author":"Rabinovici","year":"2022","journal-title":"Alzheimer's. and Dementia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13024-022-00574-4","article-title":"ApoE in Alzheimer's disease: pathophysiology and therapeutic strategie s","volume":"17","author":"Raulin","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"B23","doi-asserted-by":"publisher","first-page":"562","DOI":"10.2214\/AJR.22.28461","article-title":"Amyloid-related imaging abnormalities: an update","volume":"220","author":"Roytman","year":"2023","journal-title":"AJR Am. J. Roentgenol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S1474-4422(20)30412-9","article-title":"APOE and Alzheimer's disease: advances in genetics, pathophysiology, a nd therapeutic approaches","volume":"20","author":"Serrano-Pozo","year":"2021","journal-title":"Lancet Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer's dis ease treated with bapineuzumab: a retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Rou ndtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement."},{"key":"B28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial i n early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril ant ibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e70176","DOI":"10.1111\/cns.70176","article-title":"Reproductive toxicity induced by serotonin-norepinephrine reuptake inh ibitors: a pharmacovigilance analysis from 2004 to 2023 based on the F aers database","volume":"30","author":"Xi","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e13231","DOI":"10.1111\/psyg.13231","article-title":"A case of severe ARIA with multiple infarctions and extensive microble eds following lecanemab administration","volume":"25","author":"Yamazaki","year":"2025","journal-title":"Psychogeriatrics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1393940","DOI":"10.3389\/fphar.2024.1393940","article-title":"Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adve rse event reporting system","volume":"15","author":"Zhao","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1559447\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T05:46:46Z","timestamp":1743572806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1559447\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":32,"alternative-id":["10.3389\/fphar.2025.1559447"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1559447","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"article-number":"1559447"}}